
Opinion|Videos|May 17, 2024
KEYNOTE-564: Adjuvant Pembrolizumab in Renal Cell Carcinoma
Dr Pal discusses the study design and results of the KEYNOTE-564 trial, and Benjamin Gerendash, MSN, RN, AGACNP-BC, discusses the management of adverse events associated with pembrolizumab.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Rezatapopt Shows 46% ORR in TP53 Y220C–Mutated Ovarian Cancer
2
Daraxonrasib Shows Antitumor Activity in RAS-Mutant NSCLC
3
G2032R Resistance Data Is Reshaping Second-Line Sequencing in ROS1+ NSCLC
4
First-Line Savolitinib/Osimertinib Improves PFS in MET+ NSCLC
5































